Clinical trials: Patients With Major Depressive Disorder
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Accelerated iTBS for Major Depression
Major depressive disorder (MDD) is a common and disabling psychiatric condition, and many patients do not achieve adequate response to standard antidepressant treatments.
- Trial name
- AIM-D (NCT07603804)
- Testing
- Accelerated Intermittent Theta Burst Stimulation (iTBS)
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Istanbul University - Cerrahpasa
Major Depressive Disorder
Cognitive Dysfunction in MDD Patients
Major Depressive Disorder (MDD) is one of the most prevalent mental diagnosis within the worldwide population. Although there is evidence about relationship between MDD and cognitive dysfunction, still the correlations between…
- Trial name
- NCT03187093
- Testing
- Vortioxetine, Escitalopram
- Where
- Ukraine
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Oleg Levada
Major Depressive Disorder, Healthy Volunteer
A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)
The study will assess the safety, tolerability, and pharmacokinetics of basimglurant compared to placebo after multiple ascending oral doses for up to 22 days in healthy subjects and in patients with MDD on stable selective…
- Trial name
- NCT02433093
- Testing
- Basimglurant
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Major Depressive Disorder
Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients
The purpose of this study is to explore the effect of an inflammatory and a psychosocial stressor and the combination thereof on mood in healthy young and elderly participants and patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01533285
- Testing
- Salmonella typhi vaccine (Typhim Vi)
- Where
- 2 sites in Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Major Depressive Disorder (MDD)
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression.
- Trial name
- AERON-1 (NCT07610473)
- Testing
- DT-101
- Where
- 23 sites in United States
- Volunteers
- 118 people
- Sponsor
- Draig Therapeutics Ltd
Major Depressive Disorder
Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide
This study is being done to look at how well people respond to two very different drug treatments for depression. Clinically, people with depression can respond differently to drug treatments for reasons which are not always…
- Trial name
- NCT00400088
- Testing
- paroxetine, lithium
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Nova Scotia Health Authority
Depressive Disorder
Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders
Major depressive disorder (MDD) is a significant cause of disability that affects approximately 16% of the world's population and is associated with chronic inflammation.
- Trial name
- NCT05792540
- Testing
- Fluoxetine 20 mg, Dapagliflozin 10mg Tab, Atorvastatin 80mg
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Tanta University
Major Depressive Disorder
Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response
The purpose is to assess the response of add-on therapy, based on CGI-I scale, at 4 weeks, in patients with MDD who had an inadequate disease control with antidepressant medication.
- Trial name
- MADDRE (NCT01397903)
- Where
- 27 sites in Greece
- Volunteers
- 545 people
- Sponsor
- AstraZeneca
Hepatitis C, Chronic, Cognition Disorders
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
Patients with HCV infection often suffer from chronic fatigue, depression and reduced cognition, even before evolving severe liver fibrosis, liver cirrhosis and hepatic encephalopathy.
- Conditions
- Hepatitis C, Chronic, Cognition Disorders, Fatigue Syndrome, Chronic, Major Depressive Disorder
- Trial name
- NCT00788918
- Testing
- Interferon and ribavirin
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Panic Disorder, Posttraumatic Stress Disorder
Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder
The purpose of this study is to examine how certain brain chemicals work in patients with Panic Disorder (PD) and Post-Traumatic Stress Disorder (PTSD) with and without major depressive disorder (MDD).
- Conditions
- Panic Disorder, Posttraumatic Stress Disorder, Major Depressive Disorder
- Trial name
- NCT00025974
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depression, Major Depressive Disorder
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work.
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Trial name
- NCT03973268
- Testing
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Mental Health (NIMH)
COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis)
Psilocybin Therapy for Psychological Distress in Palliative Patients
The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major Depressive Disorder (MDD)
- Trial name
- PsyPal (NCT06782724)
- Testing
- Psilocybin therapy
- Where
- 4 sites in Czechia, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- University Medical Center Groningen
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00256113
- Testing
- Saredutant succinate (SR48968C)
- Where
- 8 sites in Canada, Chile and 6 more
- Volunteers
- 467 people
- Sponsor
- Sanofi
Bipolar Disorder
Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder
Clinical practice indicates that Quetiapine has sedating properties, and its sedative effects may play an important role in restoring quality of sleep in patients with various psychiatric conditions who frequently experience…
- Trial name
- NCT00616889
- Testing
- Seroquel
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Queen's University
Major Depression, Epilepsy
Lexapro for Major Depression in Patients With Epilepsy
The primary objective will be to pilot the use of escitalopram for the treatment of major depression in patients with epilepsy. The secondary objectives will be to determine effect sizes on scales measuring depressive symptoms…
- Trial name
- NCT01244724
- Testing
- Lexapro
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
- Trial name
- NCT00035282
- Testing
- aprepitant
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine, Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg…
- Trial name
- NCT04041284
- Testing
- Fremanezumab
- Where
- 64 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Depression
Efficacy of Blue Light Treatment in Patients With Nonseasonal Major Depressive Disorder
To compare the efficacy of blue light, bright light and dim light in the treatment of with nonseasonal major depression disorder(MDD) in adults.
- Trial name
- NCT04555408
- Testing
- blue light, bright light, dim light
- Volunteers
- 162 people
- Sponsor
- Shanghai Zhongshan Hospital
Major Depressive Disorder
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838876
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 90 sites in United States, Puerto Rico
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories